ArticleBMC urology2025
Nomogram for predicting risk factors of postoperative residual stones in patients after pure ultrasonography-guided access mini-percutaneous nephrolithotomy.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSome urologists prefer to perform PCNL by using pure ultrasonography-guided access (USGA), but some potential factors that may cause the residual stones need to be excavated. This retrospective case-control study is designed to confirm the risk factors for residual stones after pure USGA mini-percutaneous nephrolithotomy (mPCNL) in patients and develop a nomogram for predicting postoperative residual stones based on the risk factors.
methodsFrom October 2019 to August 2021, our department recorded a retrospective record of 227 patients with kidney stones treated with pure USGA mPCNL. The risk factors for postoperative residual stones were confirmed by univariate and multivariate logistic regression analysis, and a nomogram was developed. As a result, the nomogram was accessed with discrimination, calibration, and clinical applicability in mind.
resultsThe rate of residual stones in patients was 34.4% during the management of USGA mPCNL. The independent risk factors for residual stones were history of ipsilateral PCNL surgery (OR = 3.163, P = 0.020 ), calyx number with stones (OR = 5.628, P = 0.006 ), stone burden (OR = 1.004, P = 0.008 ). Calculated by receiver operating characteristic (ROC) analysis, the area under the curve (AUC) was 0.884 (95% CI 0.829-0.940). The concordance index (C-index) of calibration curves was 0.842, meaning good concordance. The clinical decision curve analysis (DCA) showed a good clinical practicability in clinical practice.
conclusionsPatients with history of ipsilateral PCNL surgery, calyx number with stones and stone burden may be at increased risk of residual stones. The nomogram can evaluate the risk of residual stones in patients who undergo USGA mPCNL. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.